News & Updates

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

04 Oct 2022 by

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

04 Oct 2022

Early diagnosis and treatment of transthyretin amyloid cardiomyopathy significantly improves outcomes

30 Aug 2022 by

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a significantly underdiagnosed, life-threatening disease caused by the deposition of transthyretin amyloid fibrils in the heart. Dr Soon Chao Yang, Interventional Cardiologist at The Heart Doctors Clinic in Mount Alvernia Hospital, Singapore, reviews the data on early treatment of ATTR-CM, and shares his clinical experience with tafamidis.

Early diagnosis and treatment of transthyretin amyloid cardiomyopathy significantly improves outcomes

30 Aug 2022

Optimizing anticoagulation therapy for atrial fibrillation with prior gastrointestinal bleeding

24 Jul 2022 by

Long-term anticoagulation therapy is often recommended for patients with atrial fibrillation (AF) to reduce their risk of stroke, but gastrointestinal bleeding (GIB) is a common complication that presents a significant challenge. Patients with a history of GIB have heightened risks of recurrent bleeding events, hence interruption or discontinuation of anticoagulants is often warranted. When and how to restart anticoagulant therapy following an episode of GIB has been debated. MIMS Doctor interviewed Dr Pipin Kojodjojo, Cardiologist and Cardiac Electrophysiologist at Asian Heart & Vascular Centre, Singapore, to gather his perspectives on how to manage anticoagulant therapy after a GIB episode.

Optimizing anticoagulation therapy for atrial fibrillation with prior gastrointestinal bleeding

24 Jul 2022

Tafamidis still the only approved therapy for ATTR-CM in Asia

23 Jul 2022 by

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressively debilitating disease with a formidable symptom burden and an average survival of 2–5 years from diagnosis. In 2019, the US Food and Drug Administration approved tafamidis (Vyndamax) as the first disease-modifying therapy for ATTR-CM. Since then, tafamidis has been approved for the treatment of ATTR-CM in over 55 countries including Japan, Australia, and Singapore. MIMS Doctor interviewed Dr Tang Hak Chiaw, consultant cardiologist at Novena Heart Centre, Singapore, about the types and clinical presentation of ATTR-CM in Singapore, and the role of tafamidis in the treatment of this often underdiagnosed and fatal disease of the heart muscle.

Tafamidis still the only approved therapy for ATTR-CM in Asia

23 Jul 2022

$Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum$

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

06 Jun 2022

Early treatment of ATTR-CM with tafamidis increases survival

27 May 2022 by

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and life-threatening rare disease caused by unstable transthyretin proteins that misfold and aggregate into insoluble amyloid fibrils that deposit in the heart and other organs of the body. Tafamidis, a transthyretin stabilizer, is the first disease-modifying therapy approved for ATTR-CM. Clinical Assistant Professor Khoo Chun Yuan, Consultant Cardiologist at the National Heart Centre Singapore, discusses the importance of early diagnosis and treatment of ATTR-CM patients.

Early treatment of ATTR-CM with tafamidis increases survival

27 May 2022

Optimal protection in geriatric patients with atrial fibrillation: An expert’s perspective

01 Apr 2022 by

Geriatric patients with atrial fibrillation (AF) are at increased risk of blood clots that can lodge in the brain and cause fatal strokes. At a recent webinar, Professor Olivier Hanon, Head of Geriatrics Department in Broca Hospital, Paris, France, shared insights on how to optimally protect geriatric patients with AF, with a special focus on direct oral anticoagulants (DOACs), particularly rivaroxaban, for stroke prevention in AF.

Optimal protection in geriatric patients with atrial fibrillation: An expert’s perspective

01 Apr 2022

Addressing the unmet needs and challenges in managing older AF patients

01 Apr 2022 by

A key focus in the management of atrial fibrillation (AF) in older patients is stroke prevention through oral anticoagulation. However, a significant proportion of older AF patients remain undercoagulated due to the perceived bleeding risk of oral anticoagulants (OACs). Dr Tan Vern Hsen, Senior Consultant, Department of Cardiology, Changi General Hospital, Singapore, and Dr Barbara Helen Rosario, Senior Consultant, Department of Geriatric Medicine, Changi General Hospital, Singapore, shared their respective insights into managing older AF patients for an integrated approach.

Addressing the unmet needs and challenges in managing older AF patients

01 Apr 2022

Role of apixaban in VTE management: Who, when, and how

31 Mar 2022 by

Venous thromboembolism (VTE) is associated with an increased risk of morbidity and mortality. Given the challenges posed by conventional therapies used for the treatment of VTE, Dr Lim Xiu Qi Cheryl, Associate Consultant from the Department of Haematology-Oncology at National University Cancer Institute, Singapore (NCIS), shares her insights on the role of apixaban (Eliquis, Pfizer), an oral factor Xa inhibitor, in the treatment of acute VTE and prevention of recurrent VTE.

Role of apixaban in VTE management: Who, when, and how

31 Mar 2022

Vericiguat addresses unmet needs in worsening HFrEF

04 Feb 2022

Heart failure (HF) is a complicated clinical syndrome that is inherently progressive. In HF with reduced ejection fraction (HFrEF), the left ventricular ejection fraction (LVEF) is ≤40 percent and accompanied by progressive LV dilatation and adverse cardiac remodeling. [Eur J Heart Fail 2021;23:352-380]

Vericiguat addresses unmet needs in worsening HFrEF

04 Feb 2022

News & Updates

Filter by Specialty:

Specialty:

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

Early diagnosis and treatment of transthyretin amyloid cardiomyopathy significantly improves outcomes

Early diagnosis and treatment of transthyretin amyloid cardiomyopathy significantly improves outcomes

Optimizing anticoagulation therapy for atrial fibrillation with prior gastrointestinal bleeding

Optimizing anticoagulation therapy for atrial fibrillation with prior gastrointestinal bleeding

Tafamidis still the only approved therapy for ATTR-CM in Asia

Tafamidis still the only approved therapy for ATTR-CM in Asia

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

Early treatment of ATTR-CM with tafamidis increases survival

Early treatment of ATTR-CM with tafamidis increases survival

Optimal protection in geriatric patients with atrial fibrillation: An expert’s perspective

Optimal protection in geriatric patients with atrial fibrillation: An expert’s perspective

Addressing the unmet needs and challenges in managing older AF patients

Addressing the unmet needs and challenges in managing older AF patients

Role of apixaban in VTE management: Who, when, and how

Role of apixaban in VTE management: Who, when, and how

Vericiguat addresses unmet needs in worsening HFrEF

Vericiguat addresses unmet needs in worsening HFrEF